As I approached the Main Arena at the annual Transcatheter Cardiovascular Therapeutics (TCT) meeting, I saw a mass of people standing outside trying to get in. The house was packed, and the fire marshal had blocked the doors. The presentation of “Transcatheter Aortic-Valve Replacement for Asymptomatic Severe Aortic Stenosis” [ ] was attended by a standing room only crowd. It was clearly the most anticipated report at the meeting. The attendees were not disappointed as the results were announced – early TAVR was better than watchful waiting. This conclusion was based on the primary endpoint of the composite of death from any cause, stroke, or unplanned hospitalizations for cardiac causes. There were some secondary endpoints such as the Kansas City Cardiomyopathy Questionnaire (KCCQ), a measure of left ventricular and atrial function and atrial fibrillation. The main attraction, however, was the marked advantage for the early TAVR group in the primary endpoint that was driven by unplanned hospitalizations for cardiac causes. There was no difference in death and stroke. In other words, from the patient's perspective, one could view either strategy as providing the same survival chance but with a greater chance of being hospitalized.